C4 Therapeutics, Inc. (CCCC) Financials

CCCC Assets vs Liabilities

DateAssetsLiabilities
March 31, 2026 328.9 million 94.6 million
Dec. 31, 2025 359.1 million 102.5 million
Sept. 30, 2025 265.5 million 111.1 million
June 30, 2025 296.5 million 122.5 million

CCCC Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -30.0 million ?
Dec. 31, 2025 -22.2 million 4.0 million
Sept. 30, 2025 -31.6 million 4.6 million
June 30, 2025 -12.2 million 5.0 million

CCCC Net Income

No data available :(

CCCC Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 235.7 million - 51.9 million
Dec. 31, 2025 248.5 million - 53.6 million
Sept. 30, 2025 191.9 million - 61.5 million
June 30, 2025 214.6 million - 62.9 million

CCCC Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 126.1 million
Dec. 31, 2025 82.9 million
Sept. 30, 2025 72.6 million
June 30, 2025 71.0 million

CCCC Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 64000 24.6 million 7.5 million -1.8 million
Dec. 31, 2025 11000 25.0 million 9.2 million -
Sept. 30, 2025 411000 26.0 million 8.9 million -
June 30, 2025 185000 26.2 million 8.8 million -

CCCC Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 6.2 million 1.8 million
Dec. 31, 2025 11.0 million 1.8 million
Sept. 30, 2025 11.2 million -
June 30, 2025 6.5 million 2.1 million

CCCC

Price: $3.96

52 week price:
1.21
4.38

Earnings Per Share: -1.10 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 914600

Market Capitalization: 357.1 million

Links: